Verano Holdings (VRNO) Liabilities and Shareholders Equity (2021 - 2026)
Verano Holdings (VRNO) posted quarterly Liabilities and Shareholders Equity of $1.7 billion for Q1 2026, down 13.24% year-over-year from $2.0 billion in Q1 2025, and down 1.91% quarter-over-quarter from $1.7 billion in Q4 2025.
Verano Holdings (VRNO) Liabilities and Shareholders Equity (2021 - 2026) Analysis & Trends
Verano Holdings (VRNO) has reported Liabilities and Shareholders Equity for 6 consecutive years, with $1.7 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Liabilities and Shareholders Equity fell 13.24% year-over-year to $1.7 billion; the TTM figure through Mar 2026 stood at $7.3 billion (down 14.09% YoY), while the FY2025 annual figure was $1.7 billion, down 12.66% from the prior year.
- Liabilities and Shareholders Equity retreated to $1.7 billion in Q1 2026 per VRNO's latest filing, from $1.7 billion in the prior quarter.
- Across five years, Liabilities and Shareholders Equity topped out at $2.6 billion in Q3 2022 and bottomed at $1.7 billion in Q1 2026.
- Historically, Liabilities and Shareholders Equity has averaged $2.2 billion across 5 years, with a median of $2.3 billion in 2024.
- Annual changes were most pronounced in 2024 — Liabilities and Shareholders Equity dropped 1.72% — and 2025, when it dropped 16.82%.
- Verano Holdings' Liabilities and Shareholders Equity stood at $2.4 billion in 2022, then dropped by 3.23% to $2.3 billion in 2023, then decreased by 14.0% to $2.0 billion in 2024, then dropped by 12.66% to $1.7 billion in 2025, then dropped by 1.91% to $1.7 billion in 2026.
- Business Quant data shows VRNO's Liabilities and Shareholders Equity at $1.7 billion in Q1 2026, $1.7 billion in Q4 2025, and $1.9 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | 43.71 Bn |
| 2 | Teva Pharmaceutical Industries | 42.95 Bn | 39.30 Bn | 2.15 Bn | 39.86 Bn |
| 3 | Zoetis | 31.58 Bn | 29.90 Bn | 1.05 Bn | 15.08 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 98.27 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | 7.22 Bn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 35.04 Bn |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn | 5.36 Bn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 13.56 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | 6.18 Bn |
| 10 | Verano Holdings | 438.82 Mn | 353.62 Mn | 99.70 Mn | 1.70 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.70 Bn |
| Mar 31, 2026 | 1.71 Bn |
| Dec 31, 2025 | 1.74 Bn |
| Sep 30, 2025 | 1.93 Bn |
| Jun 30, 2025 | 1.94 Bn |
| Mar 31, 2025 | 1.97 Bn |
| Dec 31, 2024 | 1.99 Bn |
| Sep 30, 2024 | 2.31 Bn |
| Jun 30, 2024 | 2.24 Bn |
| Mar 31, 2024 | 2.32 Bn |
| Dec 31, 2023 | 2.32 Bn |
| Sep 30, 2023 | 2.36 Bn |
| Jun 30, 2023 | 2.35 Bn |
| Mar 31, 2023 | 2.37 Bn |
| Dec 31, 2022 | 2.40 Bn |
| Sep 30, 2022 | 2.62 Bn |
| Jun 30, 2022 | 2.60 Bn |
| Dec 31, 2021 | 2.55 Bn |